SELLAS Life Sciences Group Inc
NASDAQ:SLS 9:39:30 AM EDT
Products, Strategic Combinations
Sellas, 3D Medicines Announce Deal For Development, Commercialization Of Galinpepimut-S & GPS+ In Greater China
Published: 12/07/2020 13:50 GMT
SELLAS Life Sciences Group Inc (SLS) - Sellas Life Sciences and 3d Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-s (gps) and Gps+ in Greater China.
Sellas Life Sciences - to Potentially Get Up to $202 Million, Inclusive of $7.5 Million Upfront License Fee, $8 Million Near-term Milestones, Plus Tiered Royalties.
Sellas Life Sciences Group Inc - 3d Medicines to Lead Clinical Development and Commercialization of Gps and Gps+ in Greater China.
Sellas Life Sciences Group - Retains Sole Rights to Gps and Gps+ Outside of Greater China Area.
Sellas Life Sciences - to Potentially Get Up to $202 Million, Inclusive of $7.5 Million Upfront License Fee, $8 Million Near-term Milestones, Plus Tiered Royalties.
Sellas Life Sciences Group Inc - 3d Medicines to Lead Clinical Development and Commercialization of Gps and Gps+ in Greater China.
Sellas Life Sciences Group - Retains Sole Rights to Gps and Gps+ Outside of Greater China Area.